135 related articles for article (PubMed ID: 32703344)
1. Correlation between Clinical Factors and Prognosis in Newly Diagnosed Multiple Myeloma.
Zhao XQ; Zhao SY; Chen WX; Liu XW; Yan HX; Lou YJ
J Coll Physicians Surg Pak; 2020 Jun; 30(6):601-605. PubMed ID: 32703344
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
4. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between Expression Patterns of CD117/CD200 in Plasma Cells and Molecular Genetic Prognostic Parameters in Multiple Myeloma].
Wang P; Wang XD; Liu L; Chen X; Liu F; Zhao SS; Yang H; Qiu HR; Guo R; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1415-1420. PubMed ID: 37846693
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
Li F; Xu Y; An G; Hu LP; Zhang YR; Li ZJ; Yuan WP; Cheng T; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):862-7. PubMed ID: 24171960
[TBL] [Abstract][Full Text] [Related]
7. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.
Li M; Bai Y; Sun X; Wang H; Li W; Xiao X; Chen Y; Sun K
Discov Med; 2023 Apr; 35(175):157-167. PubMed ID: 37105925
[TBL] [Abstract][Full Text] [Related]
8. [Detection of del(17p13) among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance].
Lu X; Chen L; Shi Q; Qiu H; Li J; Guo R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1087-1091. PubMed ID: 32924107
[TBL] [Abstract][Full Text] [Related]
9. Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
Leone PE; Walker BA; Jenner MW; Chiecchio L; Dagrada G; Protheroe RK; Johnson DC; Dickens NJ; Brito JL; Else M; Gonzalez D; Ross FM; Chen-Kiang S; Davies FE; Morgan GJ
Clin Cancer Res; 2008 Oct; 14(19):6033-41. PubMed ID: 18829482
[TBL] [Abstract][Full Text] [Related]
10. [Clinical prognosis analysis of patients with "double hit" multiple myeloma].
Luo TC; Wu LL; Wu H; Lu M; Fu WJ; Du J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):918-923. PubMed ID: 31856440
[No Abstract] [Full Text] [Related]
11. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
[TBL] [Abstract][Full Text] [Related]
12. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
[No Abstract] [Full Text] [Related]
13. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
Hebraud B; Leleu X; Lauwers-Cances V; Roussel M; Caillot D; Marit G; Karlin L; Hulin C; Gentil C; Guilhot F; Garderet L; Lamy T; Brechignac S; Pegourie B; Jaubert J; Dib M; Stoppa AM; Sebban C; Fohrer C; Fontan J; Fruchart C; Macro M; Orsini-Piocelle F; Lepeu G; Sohn C; Corre J; Facon T; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2014 Mar; 28(3):675-9. PubMed ID: 23892719
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
15. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
Zojer N; Königsberg R; Ackermann J; Fritz E; Dallinger S; Krömer E; Kaufmann H; Riedl L; Gisslinger H; Schreiber S; Heinz R; Ludwig H; Huber H; Drach J
Blood; 2000 Mar; 95(6):1925-30. PubMed ID: 10706856
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
18. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
[TBL] [Abstract][Full Text] [Related]
19. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
Sun C; Wang J; Guo HF; Zhou X; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
[TBL] [Abstract][Full Text] [Related]
20. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
